Evaluating the Effectiveness of Genetic Testing for Personalized Treatment in Non-Small Cell Lung Cancer (NSCLC) in South Korea
Keywords:
Non-Small Cell Lung Cancer (NSCLC), genetic testing, personalized treatment, EGFR mutations, ALK rearrangements, ROS1 fusions, Tyrosine Kinase Inhibitors (TKIs)Abstract
Non-Small Cell Lung Cancer (NSCLC) represents the most prevalent type of lung cancer globally, and its treatment has been revolutionized through the integration of genetic testing, which enables personalized treatment strategies. This paper examines the effectiveness of genetic testing in NSCLC, particularly in the context of South Korea, where significant advancements in precision oncology have been made. The study explores the role of genetic testing in identifying actionable mutations such as EGFR, ALK, and ROS1, and how these genetic profiles influence treatment decisions, particularly the use of tyrosine kinase inhibitors (TKIs) and immunotherapy. Through an analysis of clinical outcomes, including patient survival rates, progression-free survival, and quality of life, the paper highlights the benefits of genetic testing in improving patient care. Furthermore, challenges such as the accessibility, affordability, and technical limitations of genetic testing are discussed, along with the need for greater integration of genetic testing in clinical practice. The ethical implications surrounding patient autonomy, informed consent, and the use of genetic data are also explored. By addressing these issues, this paper aims to provide a comprehensive understanding of the role of genetic testing in NSCLC treatment and its potential to enhance clinical outcomes in South Korea.
